Mycosis fungoides (MF), the most common type of primary cutaneous T-cell lymphoma, undergoes large cell transformation in only a minority of cases that present in patch stage. We describe a 52-year-old patient with a history of unilesional patch stage MF treated with localized radiotherapy. He had disease recurrence 5 years later and began psoralen plus ultraviolet A treatment with good response. After inguinal lymphadenopathy was detected on physical examination, a follow-up PET scan showed a fluorodeoxyglucose-avid inguinal node, which was evaluated by fine needle aspiration. Cytomorphology showed numerous Reed-Sternberg-like cells, highly suspicious for Hodgkin lymphoma. Histologic sections revealed isolated sinusoidal involvement by pleomorphic CD30-positive tumor cells, diagnostic of large cell transformation of MF in light of clinical history. The cells were also positive for CD15 and CD4. This case emphasizes morphologic features of an entity with limited description in the cytology literature and adds to the growing number of reported CD15-positive T-cell lymphomas.

1.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ: WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
2.
Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857–866.
3.
Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, Russell-Jones R: Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001;97:624–630.
4.
de Coninck EC, Kim YH, Varghese A, Hoppe RT: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001;19:779–784.
5.
Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R: Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150–1159.
6.
Barberio E, Thomas L, Skowron F, Balme B, Dalle S: Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol 2007;157:284–289.
7.
Kim YH, Martinez G, Varghese A, Hoppe RT: Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003;139:165–173.
8.
Pai RK, Mullins FM, Kim YH, Kong CS: Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. Cancer 2008;114:323–332.
9.
Galindo LM, Garcia FU, Hanau CA, Lessin SR, Jhala N, Bigler RD, Vonderheid EC: Fine-needle aspiration biopsy in the evaluation of lymphadenopathy associated with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome). Am J Clin Pathol 2000;113:865–871.
10.
Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH: Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007;143:45–50.
11.
Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S: Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513–1522.
12.
Benner MF, Jansen PM, Meijer CJ, Willemze R: Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2009;161:121–127.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.